셀큐이티 (CELC) 주가

셀큐이티(CELC)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $80.61 (-5.06%), 시가총액 $6.82B, 52주 범위 $10.44 ~ $144.98.

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc.

핵심 지표

• 현재가: $80.61 (-5.06%)
• 시가총액: $6.82B
• 52주 최저~최고: $10.44 ~ $144.98
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

셀큐이티의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

셀큐이티 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 적극 매수 (4.7 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 127.74
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문